Cargando…
Alprazolam-induced dose-dependent anorgasmia: case analysis
BACKGROUND: Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066992/ https://www.ncbi.nlm.nih.gov/pubmed/30083378 http://dx.doi.org/10.1192/bjo.2018.35 |
_version_ | 1783343071909380096 |
---|---|
author | Kaufman, Kenneth R. Coluccio, Melissa Linke, Michelle Noonan, Elizabeth Babalola, Ronke Aziz, Rehan |
author_facet | Kaufman, Kenneth R. Coluccio, Melissa Linke, Michelle Noonan, Elizabeth Babalola, Ronke Aziz, Rehan |
author_sort | Kaufman, Kenneth R. |
collection | PubMed |
description | BACKGROUND: Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular. AIMS: To report dose-dependent alprazolam anorgasmia. METHOD: Case analysis with PubMed literature review. RESULTS: A 30-year-old male psychiatric patient presented with new-onset anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, obsessive–compulsive disorder, major depression in remission, and attention-deficit hyperactivity disorder treated with escitalopram 10 mg q.a.m., gabapentin 1000 mg total daily dose, lisdexamfetamine dimesylate 70 mg q.a.m., nortriptyline 60 mg q.h.s. and alprazolam extended-release 2.5 mg total daily dose. All psychotropic doses had been constant for >6 months excluding alprazolam, which was titrated from 1 mg to 2.5 mg total daily dose. The patient denied any sexual dysfunction with alprazolam at 1 mg q.d. and 1 mg b.i.d. Within 1 week of increasing alprazolam to 2.5 mg total daily dose, the patient reported anorgasmia. Anorgasmia was alprazolam dose-dependent, as anorgasmia resolved with reduced weekend dosing (1 mg b.i.d. Saturday/1.5 mg total daily dose Sunday). CONCLUSIONS: Sexual dysfunction is an important adverse effect negatively influencing therapeutic outcome. This case reports alprazolam-induced dose-dependent anorgasmia. Clinicians/patients should be aware of this adverse effect. Routine sexual histories are indicated. DECLARATION OF INTEREST: None. |
format | Online Article Text |
id | pubmed-6066992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60669922018-08-06 Alprazolam-induced dose-dependent anorgasmia: case analysis Kaufman, Kenneth R. Coluccio, Melissa Linke, Michelle Noonan, Elizabeth Babalola, Ronke Aziz, Rehan BJPsych Open Papers BACKGROUND: Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular. AIMS: To report dose-dependent alprazolam anorgasmia. METHOD: Case analysis with PubMed literature review. RESULTS: A 30-year-old male psychiatric patient presented with new-onset anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, obsessive–compulsive disorder, major depression in remission, and attention-deficit hyperactivity disorder treated with escitalopram 10 mg q.a.m., gabapentin 1000 mg total daily dose, lisdexamfetamine dimesylate 70 mg q.a.m., nortriptyline 60 mg q.h.s. and alprazolam extended-release 2.5 mg total daily dose. All psychotropic doses had been constant for >6 months excluding alprazolam, which was titrated from 1 mg to 2.5 mg total daily dose. The patient denied any sexual dysfunction with alprazolam at 1 mg q.d. and 1 mg b.i.d. Within 1 week of increasing alprazolam to 2.5 mg total daily dose, the patient reported anorgasmia. Anorgasmia was alprazolam dose-dependent, as anorgasmia resolved with reduced weekend dosing (1 mg b.i.d. Saturday/1.5 mg total daily dose Sunday). CONCLUSIONS: Sexual dysfunction is an important adverse effect negatively influencing therapeutic outcome. This case reports alprazolam-induced dose-dependent anorgasmia. Clinicians/patients should be aware of this adverse effect. Routine sexual histories are indicated. DECLARATION OF INTEREST: None. Cambridge University Press 2018-07-17 /pmc/articles/PMC6066992/ /pubmed/30083378 http://dx.doi.org/10.1192/bjo.2018.35 Text en © The Royal College of Psychiatrists 2018 http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. |
spellingShingle | Papers Kaufman, Kenneth R. Coluccio, Melissa Linke, Michelle Noonan, Elizabeth Babalola, Ronke Aziz, Rehan Alprazolam-induced dose-dependent anorgasmia: case analysis |
title | Alprazolam-induced dose-dependent anorgasmia: case analysis |
title_full | Alprazolam-induced dose-dependent anorgasmia: case analysis |
title_fullStr | Alprazolam-induced dose-dependent anorgasmia: case analysis |
title_full_unstemmed | Alprazolam-induced dose-dependent anorgasmia: case analysis |
title_short | Alprazolam-induced dose-dependent anorgasmia: case analysis |
title_sort | alprazolam-induced dose-dependent anorgasmia: case analysis |
topic | Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066992/ https://www.ncbi.nlm.nih.gov/pubmed/30083378 http://dx.doi.org/10.1192/bjo.2018.35 |
work_keys_str_mv | AT kaufmankennethr alprazolaminduceddosedependentanorgasmiacaseanalysis AT colucciomelissa alprazolaminduceddosedependentanorgasmiacaseanalysis AT linkemichelle alprazolaminduceddosedependentanorgasmiacaseanalysis AT noonanelizabeth alprazolaminduceddosedependentanorgasmiacaseanalysis AT babalolaronke alprazolaminduceddosedependentanorgasmiacaseanalysis AT azizrehan alprazolaminduceddosedependentanorgasmiacaseanalysis |